Text Size
Trial record 15 of 232 for:    eczema
Previous Study | Return to List | Next Study

Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema

This study has been completed.
Sponsor:
Information provided by:
Almirall, S.A.
ClinicalTrials.gov Identifier:
NCT01020994
First received: November 24, 2009
Last updated: July 8, 2010
Last verified: July 2010
History of Changes
  Purpose

The aim of the study is to determine the efficacy and safety of topical application of LAS41003 in comparison to LAS189962 and LAS189961 in the treatment of superinfected eczema.


Condition Intervention Phase
Eczema
 Drug: LAS41003
Drug: LAS189962
Drug: LAS189961
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema

Resource links provided by NLM:

MedlinePlus related topics: Eczema
U.S. FDA Resources

Further study details as provided by Almirall, S.A.:

Primary Outcome Measures:
  • Combination of clinical and microbial treatment success [ Time Frame: Day 14 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety:Physical examination at EoT, AEs/SAEs during the entire study [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 150
Study Start Date: November 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LAS41003 Drug: LAS41003
Once daily, topically
Active Comparator: LAS189962 Drug: LAS189962
Once daily, topically
Active Comparator: LAS189961 Drug: LAS189961
Once daily, topically

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinically diagnosed super-infected or impetiginized eczema

Exclusion Criteria:

  • Patients who have general signs of systemic infections like fever, malaise, lymphangitis or swollen lymph nodes and / or need systemic antibiotic treatment
  • Patients who have a bacterial skin infection which, due to depth and severity, could not be appropriately treated with a topical antimicrobial or antiseptic medication

  • Diagnose of the following disease:

    • Known active tuberculosis or any history of past tuberculosis of skin
    • Suspected or proven parasitic infection of the treatment site (e.g. scabies)
    • Psoriasis
    • Suspected or proven viral infection of skin (e.g. Herpes)

  • Localization of the superficial infected eczema:

    • Palms of the hands
    • Sole of a foot
    • Face
  • Have received any topical treatment with antibiotics, antimycotics, immunomodulators and corticosteroid preparations within the last 2 weeks before treatment with IMP
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01020994

Locations
Germany
Investigational Site
Bochum, Germany
Sponsors and Collaborators
Almirall, S.A.
Investigators
Study Director: Christoph Willers, MD, MBA Almirall Hermal GmbH
  More Information

No publications provided

Responsible Party: Head of Global Clinical Development, Almirall Hermal GmbH
ClinicalTrials.gov Identifier: NCT01020994     History of Changes
Other Study ID Numbers: H 552 000 - 0911, EudraCT: 2009-011931-11
Study First Received: November 24, 2009
Last Updated: July 8, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Almirall, S.A.:
Superficial infected eczema
Superinfected eczema

Additional relevant MeSH terms:
Eczema
Dermatitis
Skin Diseases
Skin Diseases, Eczematous

ClinicalTrials.gov processed this record on May 22, 2013